METHOD FOR PREDICTING COURSE OF SEVERE COPD ACCORDING TO GOLD III IN PERIOD OF EXACERBATION Russian patent published in 2021 - IPC A61B5/205 A61B5/83 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of medical diagnostics in angiology and pulmonology, and can be used in pulmonological and therapeutic hospitals to assess and predict the condition of patients with severe chronic obstructive pulmonary disease (hereinafter – COPD) of severe decease state (GOLD III) during exacerbation. As a set of prognostic methods of instrumental examination, spirometry with the determination of forced expiratory volume (hereinafter – FEV1) is used upon admission to the hospital, and immediately after the patient wakes up in the supine position, ultrasound Doppler sonography is performed to determine the speed and asymmetry of blood flow through the internal jugular veins and to determine the speed, direction and asymmetry of blood flow through the orbital veins. During sleep, cardiorespiratory monitoring is performed, determining the apnea/hypopnea index to determine whether the patient has venous encephalopathy of awakening. At the same time, as criteria for an unfavorable prognosis of the further course of COPD with the transition to an extremely severe form (GOLD IV), an increase in the maximum linear blood flow speed in the lower bulb of the internal jugular veins - more than 40 cm/s in combination with an asymmetry of blood flow of more than 45%; an increase in the maximum linear blood flow speed through the orbital veins - more than 30 cm/s, in combination with a change in direction and the presence of blood flow asymmetry; FEV1 values - in the range of 30% ≤ FEV 1 < 39%; increased apnea/hypopnea index at the time of awakening - 33 or more per hour, as an indicator of the presence of venous encephalopathy of awakening are used. In all other cases, the prognosis of severe COPD with appropriate treatment is assessed as favorable, and the course of the disease is consistently severe.

EFFECT: method provides an accurate, more differentiated prognosis for the further course of known severe COPD (GOLD III) by defining clear criteria for the usual complex of diagnostic studies used in this pathology.

1 cl, 2 ex